Precision Pathology Laboratory Services

10/17/2025

AI is changing how we diagnose cancer - delivering earlier and less invasive detection that can lead to treatment and longer, healthier lives. The U.S. Patent Office issued its intention to award bioAffinity Technologies a patent for our AI-built algorithm and flow cytometry platform to detect lung cancer. Harnessing AI with our novel flow cytometry platform has resulted in a test that produces high-precision, standardized, data-driven results to guide physicians on next steps in care for patients at high risk for lung cancer.

The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.

09/26/2025

On World Lung Day, we celebrate the strength of patients and families facing lung disease and the hope that comes with progress in care.
At CyPath® Lung, our mission is to help detect lung cancer earlier, giving patients more time, more choices, and more moments with the people they love.
Together, let’s raise awareness and look forward to a future where healthier lungs mean longer, fuller lives.

09/23/2025

Deciding what to do with indeterminate lung nodules is a challenge.
CyPath® Lung makes it easier.
✅Noninvasive sputum collection
✅Flow cytometry analysis
✅92% sensitivity | 87% specificity
For patients: fewer unnecessary procedures.
For physicians: clearer, faster answers.
Explore how CyPath® Lung supports smarter screening in the carousel.

09/19/2025

Early detection saves lives.
CyPath® Lung offers a noninvasive and accurate test to help identify lung cancer in its earliest stages — when treatment is most effective.
By leveraging advanced flow cytometry and proprietary biomarkers, CyPath® Lung empowers physicians with better tools to support patient care.
Learn more about how this innovation is changing the way we approach lung cancer detection.
www.cypathlung.com

09/10/2025

New Case Study: CyPath® Lung Identifies Cancer in Patient with Ground-Glass Nodules
Ground-glass nodules are notoriously difficult to assess as they can mimic benign lesions and often lead to years of “watchful waiting.” But in a recent case, CyPath® Lung provided actionable results that moved beyond uncertainty and enabled timely, potentially life-saving treatment.
This case highlights how CyPath® Lung can give clinicians and patients clearer answers when traditional imaging leaves too many questions.

bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO, TX – September 9, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noni...

08/29/2025

We’re proud to share that U.S. Medicine magazine, the Voice of Federal Medicine, has featured CyPath® Lung in its August pulmonary issue.
Being recognized in a publication read by thousands of VA, DoD, and Public Health Service healthcare professionals underscores the potential benefit of our noninvasive test for veterans who are 3x more likely than the general population to qualify for lung cancer screening.
The article highlights how CyPath® Lung can lead to better detection, fewer unnecessary follow-ups and substantial cost savings, a major benefit for VA providers and the veterans they care for.

Lung cancer is the leading cause of cancer deaths in the United States. Early detection is vital, especially for veterans, who face a disproportionately high risk of lung cancer due to higher rates of smoking and other exposures.

08/28/2025

An uptick in lung cancer screening (which is a very good thing) also brings an uptick in the discovery of indeterminate lung nodules which can be difficult to assess by CT or PET. The noninvasive CyPath® Lung test demonstrates 92% sensitivity and 87% specificity in detecting cancer in nodules smaller than 20 mm. This enables physicians to identify malignancy earlier and provide patients with more informed care and improved prognostic outcomes.

See what physicians are saying about CyPath® Lung: https://bit.ly/IsraelGarcia

08/19/2025

bioAffinity Technologies (NASDAQ: BIAF, BIAFW) is pleased to announce the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to our Board of Directors.
Mr. Rios brings over 40 years of financial leadership across biotechnology, medical devices, and corporate governance, while Dr. Oppenheimer is a recognized expert in asthma and COPD with extensive clinical research and guideline development experience.
Their combined expertise will support bioAffinity’s commercial growth, expansion of CyPath® Lung, and development of companion diagnostics. We also thank Gary Rubin for his seven years of dedicated service on our Board.
🔗https://bit.ly/41Jj4YZ

08/19/2025

We are pleased to announce that our Chief Science Officer, Dr. William Bauta, will present his research poster at the American Chemical Society Annual Meeting in Washington, D.C. The presentation, titled Silencing CD320 and LRP2 is selectively toxic to cancer cells, will highlight a method to selectively kill diverse human cancer cells while maintaining the integrity of normal cells by silencing two surface receptors with siRNAs.
Presentation Details:
📅Wednesday, August 20, 2025
⌚️ 5:00-7:00 PM CST
📍 Division of Medicinal Chemistry

08/19/2025

We wrapped up AABIP 2025 on a high note!
This week, we connected with leading experts and innovators to share how CyPath® Lung is helping physicians detect lung cancer early, when treatment is most effective.
We’re grateful for the meaningful conversations, new collaborations, and the shared commitment to improving lung health. Here’s to advancing patient care together!

08/14/2025

We’re looking forward to connecting at the AABIP 2025 Conference tomorrow. Visit us at Booth 44 to learn how physicians are using CyPath® Lung as a noninvasive diagnostic tool to support early detection of lung cancer and improve patient care.

08/12/2025

When an unforeseen challenge arises, our spirit of excellence shines through. Yesterday when CyPath® Lung samples were delayed, the team worked together with all hands on deck, to ensure safe and timely transport to the lab. When patient care is at the heart of our team, it can’t skip a beat.